Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

The Effect of Statin Therapy on Serum Uric Acid Levels: A Systematic Review and Meta-analysis

Author(s): Abolfazl Akbari, Mahya Razmi, Mahdi Rafiee, Gerald F. Watts and Amirhossein Sahebkar*

Volume 31, Issue 13, 2024

Published on: 27 March, 2023

Page: [1726 - 1739] Pages: 14

DOI: 10.2174/0929867330666230207124516

Price: $65

Abstract

Background: Elevated concentrations of serum uric acid (SUA) are associated with several conditions, including cardiovascular disease. The present study aimed to estimate the impact of statin therapy on SUA levels through a systematic review and meta-analysis of clinical trials.

Methods: PubMed, Embase, Web of Science, and Scopus were searched on January 14, 2022, to identify eligible clinical trials. The intervention group received statins as monotherapy or in combination with other drugs, and the control group received non-statins or placebo. Studies reporting SUA levels before and after treatment were selected for further analysis. Finally, the data were pooled, and the mean changes in SUA, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides were reported.

Results: Out of 1269 identified studies, 23 were included in the review. A total of 3928 participants received statin therapy, and 1294 were included in control groups. We found a significant reduction in SUA levels following statin therapy (mean difference (MD) = -26.67 μmol/L with 95% confidence interval (CI) [-44.75, -8.60] (P =0.004)). Atorvastatin (MD = -37.93 μmol/L [-67.71, -8.15]; P < 0.0001), pravastatin (MD = -12.64 μmol/L [-18.64, -6.65]; P < 0.0001), and simvastatin (MD = -5.95 μmol/L [-6.14, -5.80]; P < 0.0001), but not rosuvastatin, were significantly associated with a reduction in SUA levels. An analysis comparing different types of statins showed that pravastatin 20-40 mg/day could significantly reduce SUA when compared to simvastatin 10-20 mg/day (-21.86 μmol/L [-36.33,-7.39]; P =0.003).

Conclusion: Statins were significantly associated with a decrease in SUA levels, particularly atorvastatin, which was found to be most effective in lowering SUA. Atorvastatin may be the most appropriate cholesterol-lowering agent for patients with or at risk of hyperuricemia.

« Previous Next »
[1]
Deedwania, P.C.; Stone, P.H.; Fayyad, R.S.; Laskey, R.E.; Wilson, D.J. Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: A post hoc analysis of the SAGE trial. Drugs Aging, 2015, 32(12), 1055-1065.
[http://dx.doi.org/10.1007/s40266-015-0328-z] [PMID: 26625880]
[2]
Derosa, G.; Maffioli, P.; Reiner, Ž.; Simental-Mendía, L.E.; Sahebkar, A. Impact of statin therapy on plasma uric acid concentrations: A systematic review and meta-analysis. Drugs, 2016, 76(9), 947-956.
[http://dx.doi.org/10.1007/s40265-016-0591-2] [PMID: 27260336]
[3]
Sahebkar, A.; Chew, G.T.; Watts, G.F. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog. Lipid Res., 2014, 56(1), 47-66.
[http://dx.doi.org/10.1016/j.plipres.2014.07.002] [PMID: 25083925]
[4]
Serban, C.; Sahebkar, A.; Ursoniu, S.; Mikhailidis, D.P.; Rizzo, M.; Lip, G.Y.H.; Kees Hovingh, G.; Kastelein, J.J.P.; Kalinowski, L.; Rysz, J.; Banach, M. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci. Rep., 2015, 5(1), 9902.
[http://dx.doi.org/10.1038/srep09902] [PMID: 25970700]
[5]
Sohrevardi, S.; Nasab, F.; Mirjalili, M.; Bagherniya, M.; Tafti, A.; Jarrahzadeh, M.; Azarpazhooh, M.; Saeidmanesh, M.; Banach, M.; Jamialahmadi, T.; Sahebkar, A. Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. Arch. Med. Sci., 2019, 17(5), 1423-1428.
[http://dx.doi.org/10.5114/aoms.2019.89330] [PMID: 34522273]
[6]
Bahrami, A.; Bo, S.; Jamialahmadi, T.; Sahebkar, A. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res. Rev., 2020, 58, 101024.
[http://dx.doi.org/10.1016/j.arr.2020.101024] [PMID: 32006687]
[7]
Bland, A.R.; Payne, F.M.; Ashton, J.C.; Jamialahmadi, T.; Sahebkar, A. The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol. Res., 2022, 175, 105986.
[http://dx.doi.org/10.1016/j.phrs.2021.105986] [PMID: 34800627]
[8]
Sahebkar, A.; Kiaie, N.; Gorabi, A.M.; Mannarino, M.R.; Bianconi, V.; Jamialahmadi, T.; Pirro, M.; Banach, M. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog. Lipid Res., 2021, 84, 101127.
[http://dx.doi.org/10.1016/j.plipres.2021.101127] [PMID: 34509516]
[9]
Lin, C.F.; Chang, Y.H.; Chien, S.C.; Lin, Y.H.; Yeh, H.Y. Epidemiology of dyslipidemia in the Asia Pacific Region. Int. J. Gerontol., 2018, 12(1), 2-6.
[http://dx.doi.org/10.1016/j.ijge.2018.02.010]
[10]
Bahrami, A.; Parsamanesh, N.; Atkin, S.L.; Banach, M.; Sahebkar, A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol. Res., 2018, 135, 230-238.
[http://dx.doi.org/10.1016/j.phrs.2018.08.014] [PMID: 30120976]
[11]
Khalifeh, M.; Penson, P.; Banach, M.; Sahebkar, A. Statins as anti-pyroptotic agents. Arch. Med. Sci., 2021, 17(5), 1414-1417.
[http://dx.doi.org/10.5114/aoms/141155] [PMID: 34522271]
[12]
Koushki, K.; Shahbaz, S.K.; Mashayekhi, K.; Sadeghi, M.; Zayeri, Z.D.; Taba, M.Y.; Banach, M.; Al-Rasadi, K.; Johnston, T.P.; Sahebkar, A. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin. Rev. Allergy Immunol, 2021, 60(2), 175-199.
[http://dx.doi.org/10.1007/s12016-020-08791-9] [PMID: 32378144]
[13]
Shakour, N.; Ruscica, M.; Hadizadeh, F.; Cirtori, C.; Banach, M.; Jamialahmadi, T.; Sahebkar, A. Statins and C-reactive protein: In silico evidence on direct interaction. Arch. Med. Sci., 2020, 16(6), 1432-1439.
[http://dx.doi.org/10.5114/aoms.2020.100304] [PMID: 33224343]
[14]
Sahebkar, A.; Serban, C.; Mikhailidis, D.P.; Undas, A.; Lip, G.Y.H.; Muntner, P.; Bittner, V.; Ray, K.K.; Watts, G.F.; Hovingh, G.K.; Rysz, J.; Kastelein, J.J.; Banach, M. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb. Haemost., 2015, 114(3), 546-557.
[PMID: 26017749]
[15]
Sahebkar, A.; Serban, C.; Ursoniu, S.; Mikhailidis, D.P.; Undas, A.; Lip, G.Y.H.; Bittner, V.; Ray, K.K.; Watts, G.F.; Hovingh, G.K.; Rysz, J.; Kastelein, J.J.P.; Banach, M. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thromb. Haemost., 2016, 115(3), 520-532.
[http://dx.doi.org/10.1160/th15-08-0620] [PMID: 26632869]
[16]
Reiner, Ž.; Hatamipour, M.; Banach, M.; Pirro, M.; Al-Rasadi, K.; Jamialahmadi, T.; Radenkovic, D.; Montecucco, F.; Sahebkar, A. Statins and the COVID-19 main protease: In silico evidence on direct interaction. Arch. Med. Sci., 2020, 16(3), 490-496.
[http://dx.doi.org/10.5114/aoms.2020.94655] [PMID: 32399094]
[17]
Vahedian-Azimi, A.; Mannarino, M.; Shojaie, S.; Rahimibashar, F.; Esmaeili Gouvarchin Galeh, H.; Banach, M.; Bianconi, V.; Pirro, M.; Sahebkar, A. Effect of statins on prevalence and mortality of influenza virus infection: A systematic review and meta-analysis. Arch. Med. Sci., 2022, 18(6), 1-44.
[http://dx.doi.org/10.5114/aoms/149633]
[18]
Vahedian-Azimi, A.; Mohammadi, S.; Beni, F.; Banach, M.; Guest, P.; Jamialahmadi, T.; Sahebkar, A. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Arch. Med. Sci., 2021, 17(3), 579-595.
[http://dx.doi.org/10.5114/aoms/132950] [PMID: 34025827]
[19]
Kouhpeikar, H.; Delbari, Z.; Sathyapalan, T.; Simental- Mendía, L.E.; Jamialahmadi, T.; Sahebkar, A. The effect of statins through mast cells in the pathophysiology of atherosclerosis: A review. Curr. Atheroscler. Rep., 2020, 22(5), 19.
[http://dx.doi.org/10.1007/s11883-020-00837-9] [PMID: 32458165]
[20]
Gorabi, A.M.; Kiaie, N.; Bianconi, V.; Pirro, M.; Jamialahmadi, T.; Sahebkar, A. Statins attenuate fibrotic manifestations of cardiac tissue damage. Curr. Mol. Pharmacol., 2021, 14(5), 782-797.
[http://dx.doi.org/10.2174/1874467214666210210123206] [PMID: 33568040]
[21]
Parizadeh, S.M.R.; Azarpazhooh, M.R.; Moohebati, M.; Nematy, M.; Ghayour-Mobarhan, M.; Tavallaie, S.; Rahsepar, A.A.; Amini, M.; Sahebkar, A.; Mohammadi, M.; Ferns, G.A.A. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids, 2011, 46(4), 333-340.
[http://dx.doi.org/10.1007/s11745-010-3517-x] [PMID: 21207250]
[22]
Kuwabara, M.; Borghi, C.; Cicero, A.F.G.; Hisatome, I.; Niwa, K.; Ohno, M.; Johnson, R.J.; Lanaspa, M.A. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int. J. Cardiol., 2018, 261, 183-188.
[http://dx.doi.org/10.1016/j.ijcard.2018.03.045] [PMID: 29551256]
[23]
Athyros, V.G.; Mikhailidis, D.P.; Liberopoulos, E.N.; Kakafika, A.I.; Karagiannis, A.; Papageorgiou, A.A.; Tziomalos, K.; Ganotakis, E.S.; Elisaf, M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Nephrol. Dial. Transplant., 2006, 22(1), 118-127.
[http://dx.doi.org/10.1093/ndt/gfl538] [PMID: 16998214]
[24]
Moutzouri, E.; Liberopoulos, E.N.; Florentin, M.; Liamis, G.; Elisaf, M.S. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J. Cardiovasc. Pharmacol. Ther., 2013, 18(1), 13-18.
[http://dx.doi.org/10.1177/1074248412444463] [PMID: 22539817]
[25]
Wu, C.Y.; Hu, H.Y.; Chou, Y.J.; Huang, N.; Chou, Y.C.; Lee, M.S.; Li, C.P. High serum uric acid levels are associated with all-cause and cardiovascular, but not cancer, mortality in elderly adults. J. Am. Geriatr. Soc., 2015, 63(9), 1829-1836.
[http://dx.doi.org/10.1111/jgs.13607] [PMID: 26277576]
[26]
Ogata, N.; Fujimori, S.; Oka, Y.; Kaneko, K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids, 2010, 29(4-6), 321-324.
[http://dx.doi.org/10.1080/15257771003741323] [PMID: 20544514]
[27]
Nezami, N.; Safa, J.; Salari, B.; Ghorashi, S.; Khosraviani, K.; Davari-Farid, S.; Hashemi-Aghdam, Y.; Nargabad, O.N.; Tabrizi, J.S. Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy. Nucleosides Nucleotides Nucleic Acids, 2012, 31(4), 353-363.
[http://dx.doi.org/10.1080/15257770.2012.657763] [PMID: 22444196]
[28]
Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev., 2015, 4(1), 1.
[http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]
[29]
Cochrane handbook for systematic reviews of interventions. Version 5.0.2; Higgins, J.P., Ed.; The Cochrane Collaboration: London, 2009.
[30]
Tufanaru, C.; Munn, Z.; Aromataris, E.; Campbell, J.; Hopp, L. Systematic reviews of effectiveness; Joanna Briggs Institute reviewer’s manual: The Joanna Briggs Institute: Adelaide, Australia, 2017, pp. 3-10.
[31]
Imai, Y.; Suzuki, H.; Saito, T.; Tsuji, I.; Abe, K.; Saruta, T. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Clin. Exp. Hypertens., 1999, 21(8), 1345-1355.
[http://dx.doi.org/10.3109/10641969909070853] [PMID: 10574417]
[32]
Athyros, V.G.; Elisaf, M.; Papageorgiou, A.A.; Symeonidis, A.N.; Pehlivanidis, A.N.; Bouloukos, V.I.; Milionis, H.J.; Mikhailidis, D.P. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am. J. Kidney Dis., 2004, 43(4), 589-599.
[http://dx.doi.org/10.1053/j.ajkd.2003.12.023] [PMID: 15042535]
[33]
Athyros, V.G.; Mikhailidis, D.P.; Papageorgiou, A.A.; Didangelos, T.P.; Peletidou, A.; Kleta, D.; Karagiannis, A.; Kakafika, A.I.; Tziomalos, K.; Elisaf, M. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism, 2005, 54(8), 1065-1074.
[http://dx.doi.org/10.1016/j.metabol.2005.03.010] [PMID: 16092057]
[34]
Balaguer, C.; Peralta, A.; Ríos, Á.; Iglesias, A.; Valera, J.L.; Noguera, A.; Soriano, J.B.; Agustí, À.; Sala-Llinas, E. Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial. Contemp. Clin. Trials Commun., 2016, 2, 91-96.
[http://dx.doi.org/10.1016/j.conctc.2015.12.008] [PMID: 29736450]
[35]
Fassett, R.G.; Robertson, I.K.; Ball, M.J.; Geraghty, D.P.; Coombes, J.S. Effects of atorvastatin on oxidative stress in chronic kidney disease. Nephrology (Carlton), 2015, 20(10), 697-705.
[http://dx.doi.org/10.1111/nep.12502] [PMID: 25959591]
[36]
Ge, C.J.; Lu, S.Z.; Chen, Y.D.; Wu, X.F.; Hu, S.J.; Ji, Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels, 2008, 23(2), 91-95.
[http://dx.doi.org/10.1007/s00380-007-1008-7] [PMID: 18389332]
[37]
Gleim, G.; Ballantyne, C.M.; Liu, N.; Thompson-Bell, S.; McCrary Sisk, C.; Pasternak, R.C. Efficacy and safety profile of coadministered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br. J. Cardiol., 2009, 16(2), 90.
[38]
Iwata, A.; Miura, S.; Tanaka, T.; Ike, A.; Sugihara, M.; Nishikawa, H.; Kawamura, A.; Saku, K. Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin. Coron. Artery Dis., 2012, 23(5), 315-321.
[http://dx.doi.org/10.1097/MCA.0b013e328352ffec] [PMID: 22617341]
[39]
Kostapanos, M.S.; Milionis, H.J.; Gazi, I.; Kostara, C.; Bairaktari, E.T.; Elisaf, M. Rosuvastatin increases α-1 microglobulin urinary excretion in patients with primary dyslipidemia. J. Clin. Pharmacol., 2006, 46(11), 1337-1343.
[http://dx.doi.org/10.1177/0091270006292629] [PMID: 17050799]
[40]
Krysiak, R.; Kowalcze, K.; Bednarska-Czerwińska, A.; Okopień, B. The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study. Pharmacol. Rep., 2019, 71(3), 417-421.
[http://dx.doi.org/10.1016/j.pharep.2019.01.014] [PMID: 31003151]
[41]
Ruscica, M.; Gomaraschi, M.; Mombelli, G.; Macchi, C.; Bosisio, R.; Pazzucconi, F.; Pavanello, C.; Calabresi, L.; Arnoldi, A.; Sirtori, C.R.; Magni, P. Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. J. Clin. Lipidol., 2014, 8(1), 61-68.
[http://dx.doi.org/10.1016/j.jacl.2013.11.003] [PMID: 24528686]
[42]
Taheri, F.; Taheri, M.; Basiri, A.; Khoshdel, A.; Samadian, F.; Tavasoli, S. Effects of short-term atorvastatin use in patients with calcium stones: A randomized placebo-controlled clinical trial. Investig. Clin. Urol., 2019, 60(6), 472-479.
[http://dx.doi.org/10.4111/icu.2019.60.6.472] [PMID: 31692870]
[43]
Tam, L-S.; Li, E.K.; Shang, Q.; Tomlinson, B.; Lee, V.W.; Lee, K.K.; Li, M.; Kuan, W.P.; Li, T.K.; Tseung, L.; Yip, G.W.K.; Freedman, B.; Yu, C-M. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scand. J. Rheumatol., 2011, 40(6), 411-421.
[http://dx.doi.org/10.3109/03009742.2011.586649] [PMID: 21867445]
[44]
Tousoulis, D.; Andreou, I.; Tsiatas, M.; Miliou, A.; Tentolouris, C.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C.A.; Dimopoulos, M.A.; Stefanadis, C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress. Atherosclerosis, 2011, 214(1), 151-157.
[http://dx.doi.org/10.1016/j.atherosclerosis.2010.11.002] [PMID: 21122851]
[45]
Milionis, H.J.; Kakafika, A.I.; Tsouli, S.G.; Athyros, V.G.; Bairaktari, E.T.; Seferiadis, K.I.; Elisaf, M.S. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am. Heart J., 2004, 148(4), 635-640.
[http://dx.doi.org/10.1016/j.ahj.2004.04.005] [PMID: 15459594]
[46]
Milionis, H.J.; Rizos, E.; Kostapanos, M.; Filippatos, T.D.; Gazi, I.F.; Ganotakis, E.S.; Goudevenos, J.; Mikhailidis, D.P.; Elisaf, M.S. Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr. Med. Res. Opin., 2006, 22(6), 1123-1131.
[http://dx.doi.org/10.1185/030079906X112462] [PMID: 16846545]
[47]
Saku, K.; Zhang, B.; Noda, K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (Quantity and Quality of LDL)-The patrol trial. Circ. J., 2011, 75(6), 1493-505.
[48]
Matsushita, K; Hibi, K; Komura, N; Akiyama, E; Maejima, N; Iwahashi, N Effects of 4 statins on regression of coronary plaque in acute coronary syndrome. Circulat. J., 2016, 80(7), 1634-43.
[49]
Khan, M.; Murti, K.; Grover, V.; Lal, K.; Singh, D.; Das, P. Atorvastatin vs. rosuvastatin; fenofibrate as an add on: an exploratory study. Int. J. Pharm. Pharm. Sci., 2014, 6, 493-498.
[50]
Milionis, H.J.; Papakostas, J.; Kakafika, A.; Chasiotis, G.; Seferiadis, K.; Elisaf, M.S. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J. Clin. Pharmacol., 2003, 43(8), 825-830.
[http://dx.doi.org/10.1177/0091270003255920] [PMID: 12953339]
[51]
Passi, S.; Stancato, A.; Aleo, E.; Dmitrieva, A.; Littarru, G.P. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors, 2003, 18(1-4), 113-124.
[http://dx.doi.org/10.1002/biof.5520180213] [PMID: 14695926]
[52]
Murphy, C.; Deplazes, E.; Cranfield, C.G.; Garcia, A. The role of structure and biophysical properties in the pleiotropic effects of statins. Int. J. Mol. Sci., 2020, 21(22), 8745.
[http://dx.doi.org/10.3390/ijms21228745] [PMID: 33228116]
[53]
Cappuccio, F.P.; Strazzullo, P.; Farinaro, E.; Trevisan, M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA, 1993, 270(3), 354-359.
[http://dx.doi.org/10.1001/jama.1993.03510030078038] [PMID: 8315780]
[54]
Li, F.; Guo, H.; Zou, J.; Chen, W.; Lu, Y.; Zhang, X.; Fu, C.; Xiao, J.; Ye, Z. The association of urinary sodium and potassium with renal uric acid excretion in patients with chronic kidney disease. Kidney Blood Press. Res., 2018, 43(4), 1310-1321.
[http://dx.doi.org/10.1159/000492590] [PMID: 30099444]
[55]
Woodward, O.M.; Köttgen, A.; Coresh, J.; Boerwinkle, E.; Guggino, W.B.; Köttgen, M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. USA, 2009, 106(25), 10338-10342.
[http://dx.doi.org/10.1073/pnas.0901249106] [PMID: 19506252]
[56]
Rodrigues, A.C.; Curi, R.; Genvigir, F.D.V.; Hirata, M.H.; Hirata, R.D.C. The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells. Acta Pharmacol. Sin., 2009, 30(7), 956-964.
[http://dx.doi.org/10.1038/aps.2009.85] [PMID: 19543298]
[57]
Ali, N.; Rahman, S.; Islam, S.; Haque, T.; Molla, N.H.; Sumon, A.H.; Kathak, R.R.; Asaduzzaman, M.; Islam, F.; Mohanto, N.C.; Hasnat, M.A.; Nurunnabi, S.M.; Ahmed, S. The relationship between serum uric acid and lipid profile in Bangladeshi adults. BMC Cardiovasc. Disord., 2019, 19(1), 42.
[http://dx.doi.org/10.1186/s12872-019-1026-2] [PMID: 30791868]
[58]
Choi, H.K.; Mount, D.B.; Reginato, A.M. Pathogenesis of gout. Ann. Intern. Med., 2005, 143(7), 499-516.
[http://dx.doi.org/10.7326/0003-4819-143-7-200510040-00009] [PMID: 16204163]
[59]
Zhang, Z.; Xu, M.; Wei, F.; Shang, L. Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis. Pak. J. Med. Sci., 2020, 36(6), 1334-1338.
[http://dx.doi.org/10.12669/pjms.36.6.2945] [PMID: 32968404]
[60]
Keller, S.F.; Rai, S.K.; Lu, N.; Oza, A.; Jorge, A.M.; Zhang, Y.; Choi, H.K. Statin use and mortality in gout: A general population-based cohort study. Semin. Arthritis Rheum., 2018, 48(3), 449-455.
[http://dx.doi.org/10.1016/j.semarthrit.2018.03.007] [PMID: 29801703]
[61]
Xilifu, D.; Abudula, A.; Rehemu, N.; Zhao, L.; Zhou, X.; Zhang, X. Effect of rosuvastatin on hyperuricemic rats and the protective effect on endothelial dysfunction. Exp. Ther. Med., 2014, 8(6), 1683-1688.
[http://dx.doi.org/10.3892/etm.2014.2027] [PMID: 25371715]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy